Clinical Trials Browser

Active not recruiting × Ado-Trastuzumab Emtansine × 30 days × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Phase 1/2 Active not recruiting

Brain Neoplasms

NCT03587740 2026-05-18

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

111 enrolled 20 charts

Breast Neoplasms

NCT04622319 2026-05-15

DESTINY-Breast05

Phase 3 Active not recruiting

1,600 enrolled 1 FDA

HER2-Positive Primary Breast Cancer

NCT06663787 2026-05-13

HER2 CR

Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04439110 2026-05-08

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Phase 2 Active not recruiting

38 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors